-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] In recent years, the state has been vigorously supporting and promoting the development of traditional Chinese medicine, promoting the inheritance and innovation of traditional Chinese medicine, and adhering to both Chinese and Western medicine
.
In this context, it has also brought more policy dividends and new demands to the traditional Chinese medicine industry
.
It is worth noting that, due to the strong support and promotion of the development of traditional Chinese medicine by the state and the continuous expansion of market demand for traditional Chinese medicine, the traditional Chinese medicine sector has been strengthening frequently this year
.
Today, the A-share traditional Chinese medicine sector has strengthened again after the opening, and the stock prices of Hongri Pharmaceutical, Teyi Pharmaceutical, Zhongheng Group, Taiji Group, and Tasly have risen
.
Among them, Longjin Pharmaceutical, Dali Pharmaceutical, and Miracle Pharmaceutical also have daily limit
.
Specifically, Longjin Pharmaceutical was established on September 16, 1996.
The company has been focusing on the development, research, production and sales of therapeutic drugs in the two fields of cardiovascular and cerebrovascular diseases and metabolic diseases
.
In the context of the continued strength of traditional Chinese medicine stocks, Longjin Pharmaceutical has stepped out of the 4th consecutive market
.
As of press time, the stock reported 11.
02 yuan per share, up 9.
98%, with a total market value of 4.
414 billion yuan
.
According to the data, in the past five trading days, Longjin Pharmaceutical's cumulative increase has reached 46.
93%
.
In response to the stock price change, the company has announced that after verification, the controlling shareholder and actual controller have no major issues that should be disclosed but have not been disclosed about the company, and there are no major events in the planning stage
.
Miracle Pharmaceuticals also opened the daily limit at 9:38 on December 27, at 6.
09 yuan, with a turnover of 61.
1044 million yuan, and a turnover rate of 2.
14%
.
It is understood that the stock has risen by the limit 5 times in the past year
.
Regarding the stock price change, its announcement stated that there are two main reasons.
First, the company's main business is the research and development, production and sales of drugs
.
The main products include Sodium Cantharidate Vitamin B6 Injection, Sodium Cantharidate Injection, Loquat Zhike Granules, Strong Loquat Dew, Loquat Zhike Capsules, Jinwugutong Capsules, Coral Ringworm Jing, Jingwu Capsules, Quantianma Capsules, Yindanxintai Drops pills
etc.
Secondly, in recent years, the company has been actively exploring OEM brand output, commercial distribution, promoting modern logistics extension services, and exploring new business models such as third-party logistics business.
In the field of health product production, the company's front and rear industrial chain has been continuously elongated
.
In addition, Dali Pharmaceutical also hit the daily limit today.
As of 10 am, the stock price is 8.
95 yuan
.
It is worth mentioning that the stock has also increased by the limit 4 times in the past year
.
From the above overall point of view, many traditional Chinese medicine companies are expected to usher in double highs in performance and stock price in the next few years under the continuous development of the industry
.
In this regard, the industry suggests that investors can also pay more attention
.
In fact, under the background that the development of the traditional Chinese medicine sector continues to improve, investors' attention to the sector has begun to increase
.
It is understood that many brokerage institutions have expressed their optimism about the development of the traditional Chinese medicine sector
.
For example, Xiangcai Securities believes that from a policy perspective, the traditional Chinese medicine industry is expected to usher in greater policy support space than before
.
From the perspective of performance, since 2021, the revenue and net profit of the traditional Chinese medicine industry have continued to improve, and the trend of marginal improvement is expected to continue
.
From the perspective of valuation, the traditional Chinese medicine industry has obvious valuation advantages over other sub-sectors.
Therefore, "frequent favorable policies + industrial chain extension highlighting consumption attributes + absolute valuation advantages" constitute investment opportunities in the traditional Chinese medicine industry
.
According to a research report released by Kaiyuan Securities, traditional Chinese medicine, as a special type of drug in China, has always been supported by national policies; the main sales channels of branded traditional Chinese medicine OTC are at the retail end rather than public medical institutions, and have high price maintenance capabilities
.
From the perspective of policy, performance and valuation level, it is expected that some traditional Chinese medicine companies are expected to usher in the double repair of valuation and operation, and the traditional Chinese medicine sector is mainly recommended
.
In general, with the support of a series of favorable policies, the pace of development of traditional Chinese medicine will continue to accelerate
.
However, at the same time, the industry also pointed out that the traditional Chinese medicine industry urgently needs to break the bottleneck of emphasizing sales and ignoring R&D, the overall competitiveness is not strong, and the innovation vitality of enterprises is insufficient
.
Especially in the context of medical insurance cost control, traditional Chinese medicine companies urgently need to accelerate their transformation and upgrading
.
.
In this context, it has also brought more policy dividends and new demands to the traditional Chinese medicine industry
.
It is worth noting that, due to the strong support and promotion of the development of traditional Chinese medicine by the state and the continuous expansion of market demand for traditional Chinese medicine, the traditional Chinese medicine sector has been strengthening frequently this year
.
Today, the A-share traditional Chinese medicine sector has strengthened again after the opening, and the stock prices of Hongri Pharmaceutical, Teyi Pharmaceutical, Zhongheng Group, Taiji Group, and Tasly have risen
.
Among them, Longjin Pharmaceutical, Dali Pharmaceutical, and Miracle Pharmaceutical also have daily limit
.
Specifically, Longjin Pharmaceutical was established on September 16, 1996.
The company has been focusing on the development, research, production and sales of therapeutic drugs in the two fields of cardiovascular and cerebrovascular diseases and metabolic diseases
.
In the context of the continued strength of traditional Chinese medicine stocks, Longjin Pharmaceutical has stepped out of the 4th consecutive market
.
As of press time, the stock reported 11.
02 yuan per share, up 9.
98%, with a total market value of 4.
414 billion yuan
.
According to the data, in the past five trading days, Longjin Pharmaceutical's cumulative increase has reached 46.
93%
.
In response to the stock price change, the company has announced that after verification, the controlling shareholder and actual controller have no major issues that should be disclosed but have not been disclosed about the company, and there are no major events in the planning stage
.
Miracle Pharmaceuticals also opened the daily limit at 9:38 on December 27, at 6.
09 yuan, with a turnover of 61.
1044 million yuan, and a turnover rate of 2.
14%
.
It is understood that the stock has risen by the limit 5 times in the past year
.
Regarding the stock price change, its announcement stated that there are two main reasons.
First, the company's main business is the research and development, production and sales of drugs
.
The main products include Sodium Cantharidate Vitamin B6 Injection, Sodium Cantharidate Injection, Loquat Zhike Granules, Strong Loquat Dew, Loquat Zhike Capsules, Jinwugutong Capsules, Coral Ringworm Jing, Jingwu Capsules, Quantianma Capsules, Yindanxintai Drops pills
etc.
Secondly, in recent years, the company has been actively exploring OEM brand output, commercial distribution, promoting modern logistics extension services, and exploring new business models such as third-party logistics business.
In the field of health product production, the company's front and rear industrial chain has been continuously elongated
.
In addition, Dali Pharmaceutical also hit the daily limit today.
As of 10 am, the stock price is 8.
95 yuan
.
It is worth mentioning that the stock has also increased by the limit 4 times in the past year
.
From the above overall point of view, many traditional Chinese medicine companies are expected to usher in double highs in performance and stock price in the next few years under the continuous development of the industry
.
In this regard, the industry suggests that investors can also pay more attention
.
In fact, under the background that the development of the traditional Chinese medicine sector continues to improve, investors' attention to the sector has begun to increase
.
It is understood that many brokerage institutions have expressed their optimism about the development of the traditional Chinese medicine sector
.
For example, Xiangcai Securities believes that from a policy perspective, the traditional Chinese medicine industry is expected to usher in greater policy support space than before
.
From the perspective of performance, since 2021, the revenue and net profit of the traditional Chinese medicine industry have continued to improve, and the trend of marginal improvement is expected to continue
.
From the perspective of valuation, the traditional Chinese medicine industry has obvious valuation advantages over other sub-sectors.
Therefore, "frequent favorable policies + industrial chain extension highlighting consumption attributes + absolute valuation advantages" constitute investment opportunities in the traditional Chinese medicine industry
.
According to a research report released by Kaiyuan Securities, traditional Chinese medicine, as a special type of drug in China, has always been supported by national policies; the main sales channels of branded traditional Chinese medicine OTC are at the retail end rather than public medical institutions, and have high price maintenance capabilities
.
From the perspective of policy, performance and valuation level, it is expected that some traditional Chinese medicine companies are expected to usher in the double repair of valuation and operation, and the traditional Chinese medicine sector is mainly recommended
.
In general, with the support of a series of favorable policies, the pace of development of traditional Chinese medicine will continue to accelerate
.
However, at the same time, the industry also pointed out that the traditional Chinese medicine industry urgently needs to break the bottleneck of emphasizing sales and ignoring R&D, the overall competitiveness is not strong, and the innovation vitality of enterprises is insufficient
.
Especially in the context of medical insurance cost control, traditional Chinese medicine companies urgently need to accelerate their transformation and upgrading
.
